New hope for Tough-to-Treat breast cancer: experimental combo enters testing
NCT ID NCT06042894
Summary
This study is testing a new drug, SI-B003, given alone or combined with another drug called BL-B01D1, for people with advanced HER2-negative breast cancer that has spread or come back and cannot be removed by surgery. The main goals are to see if the treatment shrinks tumors and is safe. It is for adults whose cancer has worsened after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.